Advanced searches left 3/3

Major Depressive Disorder - Europe PMC

Summarized by Plex Scholar
Last Updated: 21 July 2022

* If you want to update the article please login/register

Cognitive outcomes are differentially associated with depression severity trajectories during psychotherapy treatment for late life major depressive disorder.

Objectives Late Life Depression is a chronic cognitive impairment that persists even after depression symptoms improve. The present research was intended to investigate cognitive consequences associated with depression severity changes during psychotherapy intervention for LLD. Multiple time points collected during the weekly psychotherapy intervention were used to calculate nonlinear trajectories of depression severity ratings using the Hamilton Depression Rating Scale. Nonlinear depression severity trajectories and post-treatment improvement in cognitive function were investigated by linear mixed-effects models. Conclusions Several types of depression change during treatment were correlated with improved cognition post-treatment, according to researchers. Conclusions The heterogeneity of depression trajectories linked to higher cognitive outcomes suggests that the temporal structure of depression response may have a deterministic cognitive function. The use of nonlinear depression severity trajectories, according to the study's findings, may help to clarify confusing links between depression onset and psychotherapy outcomes in LLD.

Source link: https://europepmc.org/article/MED/35822633


NLRP3 Inflammasome, NEK7 and Major Depressive Disorder

Background: For a long time, inflammation and depression have been linked to depression. In a drug-naive research sample, we aimed to investigate the correlation between NLRP3 inflammasome and its regulatory protein NEK7 with significant depressive disorder. Patients with significant depressive disorder had elevated gene expressions of NLRP3 and ASC relative to healthy controls. Conclusion: The results of this research point to the presence of NLRP3 inflammasome in the risk of major depressive disorder.

Source link: https://europepmc.org/article/PPR/PPR520234


Association between thyroid function and comorbid anxiety in first-episode and drug naïve patients with major depressive disorder.

This review was done to determine thyroid function in a large sample of first episode drug nau00efve MDD patients with and without anxiety. Compared to MDD patients without anxiety, MDD patients with anxiety were more likely to experience more suicide attempts and psychotic signs, as well as higher serum TSH, TPOAb, and TGAb levels. 1. 657 for elevated TSH levels, 1. 943 for elevated TGAb levels, and 2. 448 for elevated TPOAb levels. Conclusions Our findings show that comorbid fear in FEDN MDD patients is positively linked to elevated TSH and TGAb levels, which may be useful biomarkers of comorbidity in MDD patients. In MDD patients with impaired thyroid function, clinical treatment of diminished thyroid function may be helpful in comorbid anxiety.

Source link: https://europepmc.org/article/MED/35851661


Safety and Feasibility of Faecal Microbiota Transplant for Major Depressive Disorder: Study Protocol for a Pilot Randomised Controlled Trial

Existing conventional depression drugs have significant risks, and there have been no new treatments in decades. The microbiota-gut-brain-axis is now being acknowledged as a key to mental and brain health, and promising preclinical and clinical results show that Faecal Microbiota Transplants can be highly useful for treating a variety of mental disorders. However, there are no existing published studies in humans evaluating the effectiveness of FMT for MDD. Methods: and design : This article describes an 8-week, triple-blind, 2:1 parallel group, randomised controlled pilot trial of enema-based FMT therapy in adults with moderate-to-severe MDD. The primary objectives of the research were to determine the suitability and safety of FMT as an adjunctive therapy for MDD in adults. If this report shows that our FMT program is safe and viable, a larger fully powered RCT is recommended. Australian and New Zealand Clinical Trials Registry Registrar Registration of Trial Registration ACTRN126210009328646449664646464646464646469648464436464646464646464346464646456646464646464446458646440009328646464646468646464646464646464646484646464646964646464848464646443646464690001262100093000930009327000932864.

Source link: https://europepmc.org/article/PPR/PPR519949


Prolonged longitudinal transcutaneous auricular vagus nerve stimulation effects on striatal functional connectivity in patients with major depressive disorder

Patients with significant depressive disorder have been found to have immediate transcutaneous auricular vagus nerve stimulation, which has been shown to modulate ventral striatial functional connectivity. To determine the effect of taVNS on the FC of striatal subregions in patients with MDD patients, we used resting state functional magnetic resonance MRI. The reduced Hamilton Depression Scale scores were positively correlated with the evolution of rsFCs between left ventral prefrontal cortex and right ventral prefrontal cortex, and they were negatively linked to the change of rsFCs between left ventral cortex and right ventral prefrontal cortex, which was positively correlated with the improvement of rsFCs between left ventral caudate and right ventral prefrontal cortex, which was positively correlated with the transition of rs Right nucleus accumbens and right dorsal medial prefrontal cortex at baseline, which is a predictor of longitudinal taVNS results on HAMD scores at 8 weeks, according to the rsFC. The consistency of rsFC between the right NAc and right dmPFC may be a potential biomarker for the long-term tavNS and treatment response responses.

Source link: https://europepmc.org/article/PPR/PPR519903


C-Reactive Protein and the Kynurenic Acid to Quinolinic Acid Ratio are Independently Associated with White Matter Integrity in Major Depressive Disorder.

Kynurenine pathway metabolites with neuroprotective and neurotoxic characteristics, respectively, are neuroactive kynurenic acid and quinolinic acid. The ratio of KynA to QA in the blood has been reduced in major depressive disorder, and has been positively associated with gray matter volume in depression, according to an analysis. Participants in the Tulsa 1000 study with a DSM-V diagnosis of MDD underwent diffusion tensor imaging and obtained a serum sample for the determination of CRP, KynA, and QA. These results, taken together, are consistent with the hypothesis that within a subset of MDD patients, a higher level of systemic inflammation alters the balance of KP metabolism, but also increases the possibility that CRP and neuroactive KP metabolites represent independent molecular mechanisms that underlie white matter changes in MDD.

Source link: https://europepmc.org/article/MED/35853557


Socioeconomic differences in major depressive disorder onset among adults are partially explained by lifestyle factors: A longitudinal analysis of the Lifelines Cohort Study.

Background Major depressive disorder onset is influenced by socioeconomic status, which could be explained by lifestyle causes, but no one is aware of this route. Methods A subset of the Lifelines Cohort Study without MDD at baseline was included. The first symptoms of MDD were determined after a median follow-up time of 3. 8 years with the Mini International Neuropsychiatric Interview. Using logistic regression analyses, the closest connections between SEP, lifestyle, and MDD onset were estimated. At a follow-up, 1864 people were reported with MDD. SEP was inversely linked to MDD onset, with education proving the most significant link. Lifestyle causes explained 18. 7 percent and 5. 9 percent of MDD onset. Lifestyle causes were not the cause of the observed differences in MDD onset. Conclusions Compared to their lower SEP peers, higher SEP individuals had a reduced risk of MDD onset.

Source link: https://europepmc.org/article/MED/35850289


Randomized, double-blind, placebo-controlled, 12-week trial of vitamin D augmentation in major depressive disorder associated with vitamin D deficiency.

The aim of randomized controlled trials of vitamin D supplementation for depression has produced contradictory findings. We conducted the first RCT of VitD supplementation trials in major depressive disorder patients with concurrently elevated VitD deficiencies. Methods We tested controlled depressed adults with a mean baseline 25D of 11. 5 ng/mL to VitD or placebo for 12 weeks. Results in a focus-to-treat review, mean Hamilton Depression Scale scores decreased from 25. 7 to 5. 7, and from 25. 8 to 5. 0 in VitD and placebo groups, respectively, according to an intention-to-treat study. No significant correlations were found between 25D levels and depression ratings over the course of the study. Importantly, endpoint escitalopram doses were 4 mg/day higher in placebo than in VitD patients and 4 mg/day higher in VitD deficient patients than in VitD deficient patients. Patients with VitD deficient depressed patients may need higher antidepressant doses to achieve benefits similar to those whose deficiency is corrected by VitD supplementation.

Source link: https://europepmc.org/article/MED/35843459


Reduced fractional anisotropy in bipolar disorder v. major depressive disorder independent of current symptoms.

Patients with bipolar disorder have decreased fractional anisotropy in comparison to patients with major depressive disorder. The aim of this study was to reproduce abnormalities in white matter microstructure in BD vs. MDD, and to determine whether these differ among depressed, euthymic, and manic moods. Methods n = 136 patients with BD were compared to age- and sex-matched MDD patients and healthy controls in this cross-sectional diffusion tensor imaging study. In large bilateral clusters, BD patients had reduced FA compared to both MDD and HC. The difference between BD and MDD was not related to depressive and manic symptom severity, mood state, and mood state, according to the authors' results. In future studies using longitudinal designs, the possibility of FA values to be used as a biomarker to distinguish BD from MDD should be explored further.

Source link: https://europepmc.org/article/MED/35833369


Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder.

This analysis compared two groups of patients with MDD experiencing or not BE symptoms to determine differences in terms of clinical signs, presence of bipolar characteristics, and antidepressant treatment outcomes. Outpatients in the Combining Medications to Enhance Depression Outcomes trial were evaluated with scales measuring depressive and hypomanic symptomatology, suicide, comorbid mental disorders, and childhood traumas. Patients with MDD were characterized by higher scores of negative self-confidence, negative outlook on future, increased risk of violence, obsessive-compulsive disorder, hypomanic signs, and suicidality among patients with MDD.

Source link: https://europepmc.org/article/MED/35815954

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions